‘Supercharged’ T-cells could treat autoimmune disorders

| | August 7, 2017

Researchers in both academia and industry are turning to immune-suppressing cells to clamp down on autoimmune disorders, and the effort is building to a fever pitch.

T cells are often thought of as key foot soldiers in the immune system’s battle against foreign invaders. But there are many kinds of T cell, each armed with a different set of skills.

People with disorders caused by an autoimmune attack often also have reduced levels of regulatory T-cell activity, leading scientists to suspect that bolstering such cells could reduce the immune system’s attack on the body.

To boost these cells, many researchers […] are turning to a molecule called interleukin-2 (IL-2). High doses of IL-2 stimulate the ‘effector’ T cells that attack invaders.

Related article:  Kuwait’s blanket genetic sampling efforts may harm its economy and science

There are still concerns about how specific the IL-2 treatment can be — any potential stimulation of effector T-cell responses in a patient who is already undergoing an autoimmune attack could be dangerous. “It’s a robust field, but a challenging field,” says Jeffrey Bluestone, an immunologist at the University of California […] “It’s still unclear that you can get a regulatory T-specific response without any other effects.”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: Drug companies flock to supercharged T-cells in fight against autoimmune disease

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.

 

News on human & agricultural genetics and biotechnology delivered to your inbox.

Send this to a friend